Evogene (NASDAQ:EVGN) Coverage Initiated at StockNews.com

Equities researchers at StockNews.com initiated coverage on shares of Evogene (NASDAQ:EVGN) in a research note issued on Wednesday. The firm set a “sell” rating on the biotechnology company’s stock.

Separately, Alliance Global Partners reiterated a “buy” rating on shares of Evogene in a research note on Friday, March 7th.

Evogene Price Performance

EVGN opened at $1.35 on Wednesday. The stock’s 50 day moving average price is $1.49 and its 200 day moving average price is $1.86. The stock has a market cap of $7.24 million, a P/E ratio of -0.30 and a beta of 1.28. Evogene has a 12 month low of $1.20 and a 12 month high of $9.00.

Evogene (NASDAQ:EVGN) last issued its quarterly earnings results on Thursday, March 6th. The biotechnology company reported $0.06 EPS for the quarter, beating analysts’ consensus estimates of ($0.72) by $0.78. The company had revenue of $1.61 million for the quarter, compared to analyst estimates of $3.63 million. Evogene had a negative return on equity of 109.05% and a negative net margin of 314.43%. During the same period last year, the company earned ($1.30) earnings per share.

Hedge Funds Weigh In On Evogene

A hedge fund recently bought a new stake in Evogene stock. Citadel Advisors LLC purchased a new position in Evogene Ltd. (NASDAQ:EVGN) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 15,891 shares of the biotechnology company’s stock, valued at approximately $30,000. Citadel Advisors LLC owned about 0.30% of Evogene as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 10.40% of the company’s stock.

About Evogene

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.